HomeBUSINESS
BUSINESS

Daiichi Sankyo, Puma Tie Up on HER2-Targeting Combo Therapy
(Dec.14.2017)

Daiichi Sankyo and Los Angeles-based Puma Biotechnology said on December 13 that they will collaborate with the Memorial Sloan Kettering Cancer Center to explore the combination of their HER2-targeting therapies in HER-2 mutated or HER-2 positive solid tumors ...
(LOG IN FOR FULL STORY)